Investment Rating - The report maintains a "Buy" rating for 康哲药业 (0867.HK) [11] Core Views - 康哲药业's revenue for 2024 is projected at 74.69 billion HKD, a year-on-year decrease of 6.79%, while the net profit attributable to shareholders is expected to be 16.13 billion HKD, down 32.54% year-on-year [5] - The company is focusing on innovation and increasing sales promotion for new products, with R&D expenses rising by 69.1% to 330 million HKD, reflecting a commitment to enhancing its product pipeline [6] - Traditional business lines are stabilizing, with the ophthalmology and dermatology segments showing growth, indicating a shift towards new business opportunities [7] - The company is advancing its innovative drug pipeline, with multiple projects in clinical stages, including submissions for NDA applications in China [8] - 康哲药业 is expanding its overseas operations, particularly in Southeast Asia, aiming to establish a strong market presence [10] Financial Summary - For 2024, 康哲药业's revenue is expected to decline by 7%, followed by growth of 11% in 2025, 14% in 2026, and 17% in 2027 [13] - The net profit is projected to stabilize in 2025, with a slight increase in subsequent years, reflecting a recovery in profitability [13] - The gross margin is expected to remain relatively stable, with slight improvements anticipated in the coming years [13] - Key financial ratios indicate a healthy balance sheet, with a projected P/E ratio decreasing from 11.31 in 2024 to 9.15 by 2027, suggesting potential undervaluation [13]
康哲药业（00867）：产研销综合能力，海内外平台布局，创新价值亟待重估